DalCor Pharmaceuticals Stock

dalcorpharma.comHealthcare / BioTech & PharmaFounded: 2015

DalCor Pharmaceuticals, founded in 2015, is a biopharmaceutical company seeking to find better ways to treat cardiovascular disease through a combination of genetic exploration and clinical therapies. DalCor Pharmaceuticals’ proprietary development program, dalcetrapib, combines that approach to reduce the impact of myocardial infarction (MI) in patients. DalCor Pharmaceuticals is headquartered in Montreal, Canada.

Register To Buy and Sell Shares

For more details on financing and valuation for DalCor Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access DalCor Pharmaceuticals’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like DalCor Pharmaceuticals.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

DalCor Pharmaceuticals investors also invested in these private companies

CTI Life Sciences Fund
Sanderling Ventures
Investissement Quebec
Fonds de solidarité FTQ
Caisse de dépôt et placement du Québec
Fonds de Developpement Économique

Team

Management Team

David Kallend MD
Chief Scientific Officer & Chief Medical Officer
Diane Sullivan
Chief Commercial Officer
Michael Dixon
Chief Financial Officer
Fouzia Laghrissi-Thode Ph.D
Chief Executive Officer
Therese Heinonen, D.V.M.
Chief Development Officer

Board Members

Didier Leconte
Fonds de solidarité FTQ
Laurence Rulleau Ph.D
CTI Life Sciences Fund

Frequently Asked Questions About DalCor Pharmaceuticals’ Stock

plusminus
Can you buy DalCor Pharmaceuticals’ stock?
DalCor Pharmaceuticals is not publicly traded on NYSE or NASDAQ in the U.S. To buy DalCor Pharmaceuticals’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell DalCor Pharmaceuticals’ stock?
Yes, you can sell stock of a private company like DalCor Pharmaceuticals. Forge can help you sell your DalCor Pharmaceuticals stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is DalCor Pharmaceuticals’ stock price?
DalCor Pharmaceuticals is a privately held company and therefore does not have a public stock price. However, you may access DalCor Pharmaceuticals’ private market stock price with Forge Data.
plusminus
What is DalCor Pharmaceuticals’ stock ticker symbol?
DalCor Pharmaceuticals does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

DalCor Pharmaceuticals secures $80m in Series D financing
DalCor Pharmaceuticals, a Montreal-based biopharmaceutical company with a focus on addressing cardiovascular disease, has secured $80 million in Series D financing. The round was backed by Fonds de Developpement Économique managed by Investissement Québec and Fonds Propres d’ Investissement Québec. Existing investors, such as Andes Growth, TB Pharma, Fonds de solidarité FTQ and CTI Life Sciences, also participated.
Updated on: Apr 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.